Introduction
Quantitative and analytical challenges in back nearly 50 years, changes in the scientific landscape The PGRN effort is a nationwide pharmacogenetics have refocused attention on current challenges facing research initiative sponsored by the National Institutes this field. Investigating multigenic human variation, of Health. Network members submit data to a compre especially as it relates to the molecular basis of complex hensive knowledge base, PharmGKB (http://www. diseases, is a critical element of modern genetics pharmGKB.org/). The meeting focused on the analyti research. While Mendelian disease genes are typically cal and quantitative issues confronting modern genetics of recent origin and alleles have large phenotypic research. Morning sessions addressed population genet effects, complex disease traits are often characterized ics, analytical challenges in molecular epidemiology by alleles exerting small phenotypic effects. In studying and comparative genomics. Afternoon sessions featured complex diseases, Aravinda Chakravarti of The Johns selected research updates from PGRN investigators.
Hopkins University School of Medicine noted that functional tests of alleles and gene interactions must The PGRN was conceived as a network of multidisci complement gene mapping efforts, and that an essen plinary, collaborative research groups of investigators tial component of these studies is recapitulation of the examining how genetic variation contributes to interdisease trait in an experimental system. Good study individual differences in drug responses. The groups design can tease apart the many factors that produce a are charged with collecting comprehensive, integrative complex disease, including episodic and age-dependent information about proteins and gene families known to traits; gender, environment and lifestyle; unknown be important in mediating the effects of therapeutics, gene actions; positive or negative regulatory alleles; and from variations in drug metabolizing enzymes to target epigenetic phenomena. receptors. Once comprehensive biological information for particular proteins and genes and their correspond Chakravarti described recent data from his group on ing variants is known, the network will catalogue this the complex genetics of Hirschsprung disease, in which information in a manner that is accessible and inter pedigree studies of Mennonite populations combined pretable to a wide range of scientists. PharmGKB has with a genome-wide association screen have recently the capacity to collect genetic sequence information, revealed two haplotypes in the receptor tyrosine kinase display polymorphic forms, identify functional conse (RET) gene [2] . More data do not necessarily imply more information and, for any complex trait, most genetic variation is noise (including that present in candidate genes). To help explain the phenomenon, Province presented an analogy describing catching tuna with a fishing net, through which an occasional dolphin passes. In this case, the tuna represent the test hypothesis, and the dolphins are the null hypothesis. In the example, larger and more prevalent passage of dolphins constitutes 'noise'; however, increasing the fineness of the net (e.g. by applying a Bonferroni correction) severely restricts data collection such that hardly any tuna can swim through the net. This type of statistical correction can produce a large power loss, restricting the utility of such an approach.
Province suggested that pharmacogenetics research demands a separation between gene discovery and hypothesis testing. An approach pioneered in the 1940s by Hungarian mathematician Abraham Wald led to the development of a current technique called sequential multiple decision procedures, which can help remedy the problem of balancing false positives (type I error) and false negatives (type II error). Using this method lets the experimental data determine the point at which a hypothesis-generation phase should move to a true hypothesis-testing phase [3, 4] . The approach helps to optimize sample size, while limiting both false positives and false negatives.
Joseph Terwilliger of Columbia University contrasted the goals and approaches of genetics and epidemiology. Whereas epidemiology is hypothesis-based and an ascertainment bias is undesirable, genome-scanning experiments are hypothesis-free and an ascertainment bias is necessary to maximize the efficiency of mapping studies. Genetic studies with small sample sizes tend to systematically overestimate linkage disequilibrium and underestimate variation [5] . Terwilliger expressed the view that genetic approaches need an ascertainment bias because penetrance is not equivalent to detection, and that genome-scanning methods should be limited to generating hypotheses, not to testing them.
Pharmacogenetics research may benefit from using comparative genomics strategies to glean information 
PGRN research update
Selected members of the PGRN groups presented recent research findings on adrenergic pharmacology, membrane transporters and the pharmacogenomics of chemotherapy and asthma treatment.
Stephen Liggett of the University of Cincinnati pre sented recent findings on a synergistic interaction between â 1 and AE 2C -adrenergic receptor polymorphisms that may contribute to the pathology of congestive heart failure. G protein-coupled receptors constitute the largest family of signalling molecules, many of which are involved in conveying drug action. Substan tial interindividual variation exists in agonist and antagonist response directed to these receptors; the known variable response to â-blocker therapy repre sents a particularly relevant topic for pharmacogenetics investigation. Some of this variation may be attributed to polymorphisms in coding regions, which may act together to provide persistent adrenergic stimulation and promote heart failure and/or cardiac hypertrophy. Liggett described a small clinical study in which control or heart failure patients were genotyped at both the â 1 and AE 2C -adrenergic receptor loci. Logistic regression analysis was used to determine the potential effect of each genotype and the interaction between them on the risk of heart failure. Data acquired from the African American cohort in this study were analysed separately, revealing a significantly increased odds ratio for risk of heart failure in African-American subjects who are homozygous for both polymorphisms [7] .
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Kathleen Giacomini, Ira Herskowitz, and colleagues at the University of California, San Francisco (UCSF) are in the process of cataloguing the extent of human sequence variation in membrane transporters, which are impacted by many classes of medications. The group is analysing human DNA for the existence of single nucleotide polymorphisms (SNPs) in the ATP-binding cassette transporter superfamily and in solute carrier transporters. Over 600 SNPs from both coding and noncoding regions of transporter genes have been identi fied, and the average heterozygosity (ð), the likelihood that a nucleotide position will be heterozygous when compared across two chromosomes selected randomly from a population, appears to vary considerably among transporters. Giacomini reported segmental variation in amino acid diversity within transporters, with transmembrane domains having less variation than loop regions. Comparative genomics studies and functional analyses in cells have confirmed that sequence variation within evolutionarily conserved regions is more likely to alter transporter function [8] .
In collaboration with Giacomini and Herskowitz, Este ban González Burchard of UCSF has created the SOPHIE cohort, a group of ethnically diverse research volunteers from San Francisco who have agreed to participate in future pharmacogenetics studies. To date, Burchard and colleagues have recruited 577 individuals for genotyping/phenotyping studies of medications that may be affected by genetic variation of membrane transporters. Individual members of the cohort, which contains approximately 125 individuals each of Mex ican-American, African-American, Caucasian and Chi nese descent, have consented to providing DNA samples to be used in future pharmacogenetics studies. Several UCSF investigators are currently making use of the SOPHIE cohort to examine racial and ethnic variation in genes involved in drug response. Burchard noted that, although racially admixed populations make up a significant proportion of the US population and it is important that the research community include these populations in genetics studies [9, 10] , population strati fication as a result of racial admixture can be a serious obstacle to performing genetic association studies in racially admixed populations. Burchard urged the phar macogenetics research community to consider and, when necessary, correct for the presence of population stratification in genetic association studies. . The trial has ended, but the population is still under investigation. The second study, an 8-week com parison of flunisolide and conventional steroid therapy, was conducted in adults with severe asthma. Weiss reported that no single SNP in the corticotropin-releas ing hormone receptor type 1 (CRHR1) gene produced phenotypic effects in both populations, but that a common risk haplotype was present in both populations with identical effects on treatment response. The investigators modified the computer program 'haplo. score' (http://cran.r-project.org/doc/packages/haplo.score. pdf) [13] for use as a statistical tool in data analysis. The program performs score tests for association of traits to haplotypes in the presence of phase ambiguity.
In conclusion, the goal for PharmGKB, a component of the PGRN, is to provide an information resource of maximum utility to the entire research community, and to stimulate future hypothesis-driven research. PharmGKB has recently created a Web page where the pharmacogenetics community can enter gene-drug interactions where genetic variability has been ob served and associated with phenotypic variability. The PharmGKB Community Submission Project aims to catalogue important literature datasets in pharmacoge netics [14] .
The fourth annual PGRN meeting will be held in Los Angeles, California on 8-9 March 2004.
